Evidence map›Paper›PMID 29764561›Full record

ArticleBMB reports2018

MiR-204 acts as a potential therapeutic target in acute myeloid leukemia by increasing BIRC6-mediated apoptosis.

Zhiguo Wang, Hong Luo, Zehui Fang, Yanling Fan, Xiaojuan Liu, Yujing Zhang, Shuping Rui, Yafeng Chen, Luojia Hong, Jincheng Gao and 1 more

Open access · goldAbstract readNews
In one paragraph

Article in BMB reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. The IAP family member BRUCE/BIRC6: an emerging new player in balancing life and death.Apoptosis : an international journal on programmed cell death · 2026
    Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Targeting microRNA in hematologic malignancies.Current opinion in oncology · 2020
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zhiguo WangDepartment of Hematology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shanxi Province; Department of Bone Marrow Transplantation, Harbin Hematological Cancer Institute, Harbin the First Hospital, Harbin 150010, People's Republic of China.
Hong LuoDepartment of Hematology, the First Hospital of Qiqihar, Qiqihar 150001, People's Republic of China.
Zehui FangDepartment of Endocrinology, the 4th Affiliated Hospital of Harbin Medical University, Harbin 161000, Heilongjiang Province, People's Republic of China.
Yanling FanDepartment of Bone Marrow Transplantation, Harbin Hematological Cancer Institute, Harbin the First Hospital, Harbin 150010, People's Republic of China.
Xiaojuan LiuDepartment of Bone Marrow Transplantation, Harbin Hematological Cancer Institute, Harbin the First Hospital, Harbin 150010, People's Republic of China.
Yujing ZhangDepartment of Endocrinology, the 4th Affiliated Hospital of Harbin Medical University, Harbin 161000, Heilongjiang Province, People's Republic of China.
Shuping RuiDepartment of Bone Marrow Transplantation, Harbin Hematological Cancer Institute, Harbin the First Hospital, Harbin 150010, People's Republic of China.
Yafeng ChenDepartment of Bone Marrow Transplantation, Harbin Hematological Cancer Institute, Harbin the First Hospital, Harbin 150010, People's Republic of China.
Luojia HongDepartment of Endocrinology, the 4th Affiliated Hospital of Harbin Medical University, Harbin 161000, Heilongjiang Province, People's Republic of China.
Jincheng GaoDepartment of Endocrinology, the 4th Affiliated Hospital of Harbin Medical University, Harbin 161000, Heilongjiang Province, People's Republic of China.
Mei Zhang1Department of Hematology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shanxi Province, People's Republic of China.
Harbin Medical University · CNFirst Affiliated Hospital of Xi'an Jiaotong University · CNThird Affiliated Hospital of Harbin Medical University · CNQiqihar Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myeloid leukemia (AML) is one of the most common hematological malignancies all around the world. MicroRNAs have been determined to contribute various cancers initiation and progression, including AML. Although microRNA-204 (miR-204) exerts anti-tumor effects in several kinds of cancers, its function in AML remains unknown. In the present study, we assessed miR-204 expression in AML blood samples and cell lines. We also investigated the effects of miR-204 on cellular function of AML cells and the underlying mechanisms of the action of miR-204. Our results showed that miR-204 expression was significantly downregulated in AML tissues and cell lines. In addition, overexpression of miR-204 induced growth inhibition and apoptosis in AML cells, including AML5, HL-60, Kasumi-1 and U937 cells. Cell cycle analysis further confirmed an augmentation in theapoptotic subG1 population by miR-204 overexpression. Mechanistically, baculoviral inhibition of apoptosis protein repeat containing 6 (BIRC6) was identified as a direct target of miR-204. Enforcing miR-204 expression increased the luciferase activity and expression of BIRC6, as well as p53 and Bax expression. Moreover, restoration of BIRC6 reversed the pro-apoptotic effects of miR-204 overexpression in AML cells. Taken together, this study demonstrates that miR-204 causes AML cell apoptosis by targeting BIRC6, suggesting miR-204 may play an anti-carcinogenic role in AML and function as a novel biomarker and therapeutic target for the treatment of this disease. [BMB Reports 2018; 51(9): 444-449].

Indexed as

ApoptosisCell ProliferationCells, CulturedCell SurvivalDrug Screening Assays, AntitumorHumansInhibitor of Apoptosis ProteinsLeukemia, Myeloid, AcuteMicroRNAsBIRC6 protein, humanInhibitor of Apoptosis ProteinsMicroRNAsMIRN204 microRNA, human

Identifiers

PMID29764561
PMCPMC6177501
OpenAlexW2894249541

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.